CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Ozanimod
Drug: Cyclosporine

First Posted Date: 2019-11-04

Last Posted Date: 2020-08-24

Lead Sponsor: Celgene

Target Recruit Count: 40

Registration Number: NCT04149678

Locations: 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Phase 2

Recruiting

Conditions: Beta-Thalassemia

Interventions: Drug: ACE-536

First Posted Date: 2019-10-29

Last Posted Date: 2024-12-18

Lead Sponsor: Celgene

Target Recruit Count: 99

Registration Number: NCT04143724

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Local Institution - 905, Shenzhen, Guangdong, China
🇮🇳
Kamala Hospital and Research Center, Hyderabad, Andhra Pradesh, India

and more 22 locations

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: RPC-1063

First Posted Date: 2019-10-25

Last Posted Date: 2024-10-09

Lead Sponsor: Celgene

Target Recruit Count: 250

Registration Number: NCT04140305

Locations: 🇺🇸
Local Institution - 143, Saint Louis, Missouri, United States
🇺🇸
Advanced Neurology Specialists, Great Falls, Montana, United States
🇺🇸
Local Institution - 149, Teaneck, New Jersey, United States

and more 58 locations

Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort

Completed

Conditions: Hepatic Insufficiency

First Posted Date: 2019-09-20

Last Posted Date: 2020-05-21

Lead Sponsor: Celgene

Target Recruit Count: 28

Registration Number: NCT04097704

Locations: 🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States
🇺🇸
Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States
🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Japanese Pharmacokinetic Bridging Study for CC-93538

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-93538

First Posted Date: 2019-09-19

Last Posted Date: 2020-08-24

Lead Sponsor: Celgene

Target Recruit Count: 48

Registration Number: NCT04096105

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: CC-95775

First Posted Date: 2019-09-13

Last Posted Date: 2022-02-01

Lead Sponsor: Celgene

Target Recruit Count: 24

Registration Number: NCT04089527

Locations: 🇫🇷
Institut Curie, Paris, France
🇫🇷
Centre Eugene Marquis, Rennes, France
🇫🇷
Hopital Saint Louis, Paris, France

and more 2 locations

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Phase 3

Recruiting

Conditions: Myelodysplastic Syndromes (MDS)
Beta-thalassemia
Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

Interventions: Drug: Luspatercept

First Posted Date: 2019-08-21

Last Posted Date: 2024-12-20

Lead Sponsor: Celgene

Target Recruit Count: 665

Registration Number: NCT04064060

Locations: 🇫🇷
Local Institution - 304, Pierre Benite cedex, France
🇫🇷
Local Institution - 308, Strasbourg, France
🇫🇷
Local Institution - 309, Toulouse Cedex 9, France

and more 140 locations

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Phase 2

Terminated

Conditions: Liver Cirrhosis
Non-alcoholic Fatty Liver Disease

Interventions: Drug: CC-90001
Drug: Placebo

First Posted Date: 2019-08-07

Last Posted Date: 2023-06-07

Lead Sponsor: Celgene

Target Recruit Count: 56

Registration Number: NCT04048876

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Digestive Disease Associates, PA, Catonsville, Maryland, United States

and more 139 locations

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Phase 1

Terminated

Conditions: Astrocytoma
Glioblastoma

Interventions: Drug: CC-90010

First Posted Date: 2019-08-06

Last Posted Date: 2024-07-05

Lead Sponsor: Celgene

Target Recruit Count: 20

Registration Number: NCT04047303

Locations: 🇺🇸
Local Institution - 101, Tampa, Florida, United States
🇺🇸
Local Institution - 102, Boston, Massachusetts, United States
🇪🇸
Local Institution - 302, Madrid, Spain

and more 1 locations

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-99712
Drug: BMS-986405

First Posted Date: 2019-07-29

Last Posted Date: 2024-01-30

Lead Sponsor: Celgene

Target Recruit Count: 160

Registration Number: NCT04036461

Locations: 🇺🇸
Local Institution - 102, Seattle, Washington, United States
🇺🇸
Local Institution - 104, Dallas, Texas, United States
🇨🇦
Local Institution - 202, Toronto, Ontario, Canada

and more 17 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy